B.
To urgently explain that for rare diseases, a high positive predictive value (PPV) is difficult to achieve, leading to unnecessary anxiety and follow-up for many healthy individuals. ✓
B.
To urgently implement robust data anonymization, security protocols, and obtain appropriate ethical approvals to protect patient privacy and confidentiality. ✓
C.
To collect as much data as possible without consent. ✓
B.
To urgently consider the implications of low power (high risk of Type II error) and the need for a larger, adequately powered trial before discarding a potentially beneficial therapy. ✓
C.
To fund a smaller, less expensive trial. ✓
D.
To rely solely on the current non-significant p-value. ✓
